<p>Cinctive Capital Management LP 在最近向证券交易委员会提交的 13F 表格中表示，在第三季度将其在 Vera Therapeutics, Inc.（NASDAQ:VERA - 免费报告）的持股增加了 39.5%。该基金在季度内购买了额外的 13,728 股后，持有该公司 48,500 股股票。截至其最近向证券交易委员会提交的文件，Cinctive Capital Management LP 持有的 Vera Therapeutics 约占 0.09%，价值 2,144,000 美元。</p>
<p>获取 <strong>Vera Therapeutics</strong> 的提醒：</p>
<p>其他机构投资者和对冲基金最近也增加或减少了对该公司的持股。Mirae Asset Global Investments Co. Ltd. 在第三季度将其在 Vera Therapeutics 的持股提高了 21.4%。Mirae Asset Global Investments Co. Ltd. 目前持有 1,983 股该公司的股票，价值 86,000 美元，此前在上个季度购买了额外的 350 股。科罗拉多州公共雇员退休协会在第二季度购买了价值 135,000 美元的 Vera Therapeutics 新股。Point72 Asia Singapore Pte. Ltd. 在第二季度购买了价值 163,000 美元的 Vera Therapeutics 新股。Cetera Advisors LLC 在第一季度购买了价值 235,000 美元的 Vera Therapeutics 新股。最后，Quarry LP 在第二季度购买了价值 235,000 美元的 Vera Therapeutics 新股。机构投资者目前持有该公司 99.21% 的股票。</p>
<h2>Vera Therapeutics 股价下跌 0.4%</h2>
<p>NASDAQ:VERA 的股票周二开盘价为 49.55 美元。该公司的 50 日移动平均价格为 44.21 美元，200 日移动平均价格为 39.75 美元。该公司的债务与股本比率为 0.17，流动比率为 13.76，速动比率为 13.76。Vera Therapeutics, Inc. 的一年低点为 13.09 美元，一年高点为 51.61 美元。</p>
<p>Vera Therapeutics（NASDAQ:VERA - 获取免费报告）最近于 11 月 7 日星期四发布了其财报。该公司报告本季度每股收益为（0.85 美元），低于分析师一致预期的（0.64 美元），差距为（0.21 美元）。整体而言，分析师预计 Vera Therapeutics, Inc. 本年度将发布每股收益 -2.89 美元。</p>
<h2>内部交易活动</h2>
<p>在其他新闻中，董事 Beth C. Seidenberg 于 9 月 18 日星期三出售了 1,177 股该公司的股票。股票以平均价格 42.01 美元出售，总价值为 49,445.77 美元。出售完成后，该董事现在持有 160,376 股该公司的股票，价值约为 6,737,395.76 美元。这代表其持股减少了 0.73%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。此外，首席执行官 Marshall Fordyce 于 9 月 11 日星期三出售了 15,625 股 Vera Therapeutics 股票。该股票以平均价格 37.50 美元出售，总交易额为 585,937.50 美元。交易完成后，首席执行官现在持有 307,972 股该公司的股票，价值约为 11,548,950 美元。此次交易使其持股减少了 4.83%。该出售的披露信息可以在这里找到。在过去三个月中，内部人士已出售 89,927 股公司股票，价值 3,800,796 美元。当前 21.70% 的股票由内部人士持有。</p>
<h2>华尔街分析师观点</h2>
<p>几家券商对 VERA 发表了评论。摩根大通将 Vera Therapeutics 的目标价格从 72.00 美元上调至 75.00 美元，并在 11 月 5 日星期二的研究报告中给予该股票 “增持” 评级。Wedbush 将 Vera Therapeutics 的目标价格从 30.00 美元上调至 38.00 美元，并在 11 月 8 日星期五的研究报告中给予该公司 “中性” 评级。加拿大丰业银行在 10 月 16 日星期三的报告中开始覆盖 Vera Therapeutics 股票。他们对该股票设定了 “行业表现优于大盘” 的评级和 60.00 美元的目标价格。Evercore ISI 在 9 月 16 日星期一的研究报告中将 Vera Therapeutics 的股票评级上调至 “强力买入”。最后，Cantor Fitzgerald 在 10 月 1 日星期二的研究报告中重申了 “增持” 评级，并设定了 107.00 美元的目标价格。目前有一位研究分析师对该股票给予持有评级，七位给予买入评级，两位给予强力买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “买入”，共识目标价格为 59.22 美元。</p>
<p><strong>查看我们最新的 VERA 股票报告</strong></p>
<h2>Vera Therapeutics 公司简介</h2>
<p>（免费报告）</p>
<p>Vera Therapeutics, Inc. 是一家临床阶段的生物技术公司，专注于开发和商业化针对严重免疫疾病患者的治疗。其主要产品候选药物是 atacicept，这是一种以皮下注射方式自我给药的融合蛋白，目前正在进行针对免疫球蛋白 A 肾病患者的 III 期临床试验；以及针对狼疮性肾炎的 II 期临床试验。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Vera Therapeutics</li>
<li>投资于高市盈率成长股</li>
<li>如何掌握交易纪律：克服情绪挑战</li>
<li>什么是日经 225 指数？</li>
<li>特朗普税改：2025 年可能受益的 7 只股票</li>
<li>万亿美元市值的意义超越数字</li>
<li>3 只接近 52 周低点的股票：为什么它们今天可能是明智的购买</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<p>→ 这家公司将赢得人工智能竞赛（来自 Porter &amp; Company）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDYzMg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDYzMg"/></p>
<h2>你现在应该投资 1000 美元在 Vera Therapeutics 吗？</h2>
<p>在考虑 Vera Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而 Vera Therapeutics 并不在名单上。</p>
<p>虽然 Vera Therapeutics 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

VERA

<p>Cinctive Capital Management LP 在第三季度将其在 Vera Therapeutics, Inc. (NASDAQ:VERA) 的持股增加了 39.5%，额外购买了 13,728 股，总持股量达到 48,500 股。机构投资者目前持有该公司 99.21% 的股份。Vera 的股票开盘价为 0.55 美元，52 周区间为 0.09 至 0.61 美元。分析师的评级各异，普遍共识为 “买入”，目标价为 22 美元。该公司报告每股亏损 0.85 美元，未达到预期。内部交易活动包括董事 Beth C. Seidenberg 和首席执行官 Marshall Fordyce 的股票出售</p>

<p>Cinctive Capital Management LP raised its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 39.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund owned 48,500 shares of the company's stock after purchasing an additional 13,728 shares during the quarter. Cinctive Capital Management LP owned approximately 0.09% of Vera Therapeutics worth $2,144,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>Cinctive Capital Management LP 在最近向证券交易委员会提交的 13F 表格中表示，在第三季度将其在 Vera Therapeutics, Inc.（NASDAQ:VERA - 免费报告）的持股增加了 39.5%。该基金在季度内购买了额外的 13,728 股后，持有该公司 48,500 股股票。截至其最近向证券交易委员会提交的文件，Cinctive Capital Management LP 持有的 Vera Therapeutics 约占 0.09%，价值 2,144,000 美元。</p>
</div><p>Get <strong>Vera Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vera Therapeutics</strong> 的提醒：</p>
</div><p>Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Vera Therapeutics by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company's stock valued at $86,000 after buying an additional 350 shares in the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in shares of Vera Therapeutics during the second quarter worth $135,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Vera Therapeutics during the second quarter worth $163,000. Cetera Advisors LLC bought a new position in shares of Vera Therapeutics in the first quarter worth $235,000. Finally, Quarry LP purchased a new position in shares of Vera Therapeutics in the second quarter valued at $235,000. Institutional investors own 99.21% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也增加或减少了对该公司的持股。Mirae Asset Global Investments Co. Ltd. 在第三季度将其在 Vera Therapeutics 的持股提高了 21.4%。Mirae Asset Global Investments Co. Ltd. 目前持有 1,983 股该公司的股票，价值 86,000 美元，此前在上个季度购买了额外的 350 股。科罗拉多州公共雇员退休协会在第二季度购买了价值 135,000 美元的 Vera Therapeutics 新股。Point72 Asia Singapore Pte. Ltd. 在第二季度购买了价值 163,000 美元的 Vera Therapeutics 新股。Cetera Advisors LLC 在第一季度购买了价值 235,000 美元的 Vera Therapeutics 新股。最后，Quarry LP 在第二季度购买了价值 235,000 美元的 Vera Therapeutics 新股。机构投资者目前持有该公司 99.21% 的股票。</p>
</div><h2>Vera Therapeutics Trading Down 0.4 %</h2>
<div class="lb-trans"><h2>Vera Therapeutics 股价下跌 0.4%</h2>
</div><p>Shares of NASDAQ:VERA opened at $49.55 on Tuesday. The company's fifty day moving average price is $44.21 and its 200-day moving average price is $39.75. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics, Inc. has a one year low of $13.09 and a one year high of $51.61.</p>
<div class="lb-trans"><p>NASDAQ:VERA 的股票周二开盘价为 49.55 美元。该公司的 50 日移动平均价格为 44.21 美元，200 日移动平均价格为 39.75 美元。该公司的债务与股本比率为 0.17，流动比率为 13.76，速动比率为 13.76。Vera Therapeutics, Inc. 的一年低点为 13.09 美元，一年高点为 51.61 美元。</p>
</div><p>Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.21). As a group, analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.</p>
<div class="lb-trans"><p>Vera Therapeutics（NASDAQ:VERA - 获取免费报告）最近于 11 月 7 日星期四发布了其财报。该公司报告本季度每股收益为（0.85 美元），低于分析师一致预期的（0.64 美元），差距为（0.21 美元）。整体而言，分析师预计 Vera Therapeutics, Inc. 本年度将发布每股收益 -2.89 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other news, Director Beth C. Seidenberg sold 1,177 shares of the company's stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total value of $49,445.77. Following the completion of the sale, the director now owns 160,376 shares of the company's stock, valued at approximately $6,737,395.76. This represents a 0.73 % decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, CEO Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $37.50, for a total transaction of $585,937.50. Following the completion of the transaction, the chief executive officer now owns 307,972 shares in the company, valued at approximately $11,548,950. The trade was a 4.83 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 89,927 shares of company stock worth $3,800,796. 21.70% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Beth C. Seidenberg 于 9 月 18 日星期三出售了 1,177 股该公司的股票。股票以平均价格 42.01 美元出售，总价值为 49,445.77 美元。出售完成后，该董事现在持有 160,376 股该公司的股票，价值约为 6,737,395.76 美元。这代表其持股减少了 0.73%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过此链接访问。此外，首席执行官 Marshall Fordyce 于 9 月 11 日星期三出售了 15,625 股 Vera Therapeutics 股票。该股票以平均价格 37.50 美元出售，总交易额为 585,937.50 美元。交易完成后，首席执行官现在持有 307,972 股该公司的股票，价值约为 11,548,950 美元。此次交易使其持股减少了 4.83%。该出售的披露信息可以在这里找到。在过去三个月中，内部人士已出售 89,927 股公司股票，价值 3,800,796 美元。当前 21.70% 的股票由内部人士持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several brokerages have commented on VERA. JPMorgan Chase &amp; Co. raised their target price on Vera Therapeutics from $72.00 to $75.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday, November 5th. Wedbush raised their price objective on shares of Vera Therapeutics from $30.00 to $38.00 and gave the company a &#34;neutral&#34; rating in a research report on Friday, November 8th. Scotiabank began coverage on shares of Vera Therapeutics in a report on Wednesday, October 16th. They set a &#34;sector outperform&#34; rating and a $60.00 target price on the stock. Evercore ISI upgraded shares of Vera Therapeutics to a &#34;strong-buy&#34; rating in a research note on Monday, September 16th. Finally, Cantor Fitzgerald restated an &#34;overweight&#34; rating and set a $107.00 price target on shares of Vera Therapeutics in a research report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of &#34;Buy&#34; and a consensus price target of $59.22.</p>
<div class="lb-trans"><p>几家券商对 VERA 发表了评论。摩根大通将 Vera Therapeutics 的目标价格从 72.00 美元上调至 75.00 美元，并在 11 月 5 日星期二的研究报告中给予该股票 “增持” 评级。Wedbush 将 Vera Therapeutics 的目标价格从 30.00 美元上调至 38.00 美元，并在 11 月 8 日星期五的研究报告中给予该公司 “中性” 评级。加拿大丰业银行在 10 月 16 日星期三的报告中开始覆盖 Vera Therapeutics 股票。他们对该股票设定了 “行业表现优于大盘” 的评级和 60.00 美元的目标价格。Evercore ISI 在 9 月 16 日星期一的研究报告中将 Vera Therapeutics 的股票评级上调至 “强力买入”。最后，Cantor Fitzgerald 在 10 月 1 日星期二的研究报告中重申了 “增持” 评级，并设定了 107.00 美元的目标价格。目前有一位研究分析师对该股票给予持有评级，七位给予买入评级，两位给予强力买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “买入”，共识目标价格为 59.22 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on VERA</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 VERA 股票报告</strong></p>
</div><h2>Vera Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Vera Therapeutics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.</p>
<div class="lb-trans"><p>Vera Therapeutics, Inc. 是一家临床阶段的生物技术公司，专注于开发和商业化针对严重免疫疾病患者的治疗。其主要产品候选药物是 atacicept，这是一种以皮下注射方式自我给药的融合蛋白，目前正在进行针对免疫球蛋白 A 肾病患者的 III 期临床试验；以及针对狼疮性肾炎的 II 期临床试验。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Vera Therapeutics</li>
<li>Investing in the High PE Growth Stocks</li>
<li>How to Master Trading Discipline: Overcome Emotional Challenges</li>
<li>What is the Nikkei 225 index?</li>
<li>Trump Tax Reforms: 7 Stocks That Could Benefit in 2025</li>
<li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li>
<li>3 Stocks Near 52-Week Lows: Why They Could Be Smart Buys Today</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Vera Therapeutics</li>
<li>投资于高市盈率成长股</li>
<li>如何掌握交易纪律：克服情绪挑战</li>
<li>什么是日经 225 指数？</li>
<li>特朗普税改：2025 年可能受益的 7 只股票</li>
<li>万亿美元市值的意义超越数字</li>
<li>3 只接近 52 周低点的股票：为什么它们今天可能是明智的购买</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VERA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><p>→ This company will win the AI race (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 这家公司将赢得人工智能竞赛（来自 Porter &amp; Company）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDYzMg" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10632&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Vera Therapeutics right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Vera Therapeutics 吗？</h2>
</div><p>Before you consider Vera Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vera Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而 Vera Therapeutics 并不在名单上。</p>
</div><p>While Vera Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vera Therapeutics 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cinctive Capital Management LP 购买了 13,728 股 Vera Therapeutics 公司（纳斯达克股票代码：VERA）